ClinicalTrials.gg
WithdrawnNCT03017547Updated May 5, 2026

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

A Phase 2 interventional study of IC14 and Placebo in Acute Respiratory Distress Syndrome, sponsored by Implicit Bioscience. Withdrawn. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Implicit Bioscience · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
withdrawn, not enrolling

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.

Read the detailed description

Up to 160 patients with ARDS will be randomized to receive either IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 or placebo for 4 days beginning within 48 hours of meeting inclusion criteria. Study participation will be for 28 days.

02

Conditions studied

  • Acute Respiratory Distress Syndrome
03

In context

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Implicit Bioscience is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ICU admission
  2. Age 18-70 years
  3. Presence of a known ARDS clinical risk within 7 days of onset:

    1. Pneumonia
    2. Sepsis
    3. Trauma
    4. Aspiration
    5. Pancreatitis
  4. Presence of ARDS (per Berlin criteria) defined as follows:

    1. Acute onset (\<48 hours)
    2. PaO2/FiO2\<300 on PEEP≥5
    3. Bilateral opacities consistent with pulmonary edema on frontal chest radiograph not fully explained by effusions, lobar/lung collapse, or nodules.
    4. Requirement for positive pressure ventilation via endotracheal tube
  5. Anticipated duration of mechanical ventilation >48 hrs

Exclusion criteria

Exclusion Criteria:

  1. Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry
  2. Intubation for cardiopulmonary arrest
  3. Do-not-attempt resuscitation (DNAR) status
  4. Intubation for status asthmaticus, pulmonary embolus, myocardial infarction
  5. Anticipated survival \<48 hours from intubation
  6. Anticipated survival \<28 days due to pre-existing medical condition
  7. Significant pre-existing organ dysfunction

    1. Lung: Currently receiving home oxygen therapy as documented in medical record
    2. Heart: Pre-existing congestive heart failure defined as an \<20% as documented in the medical record
    3. Renal: Chronic renal failure requiring renal replacement therapy
    4. Liver: Severe chronic liver disease defined as Class C
  8. Pre-existing, ongoing

    1. Solid organ transplant recipient
    2. Chronic high-dose (equivalent to >20 mg/prednisone/day for >14 days in the last 30 days)
    3. Oncolytic drug therapy within the past 14 days
    4. Known positive with \<200 cells/mm3
  9. Current treatment with Enbrel® (etanercept), Remicade® (infliximab), Humira® (adalimumab), Cimzia® (certolizumab), or Simponi® (golimumab), Kineret® (anakinra), or Arcalyst® (rilonacept)
  10. Pregnancy
  11. History of or idiosyncratic reaction to IC14
  12. Deprivation of freedom by administrative or court order
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IC14

    IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.

    Drug: IC14

  • Placebo comparator
    Placebo

    Placebo IV once daily on Study Day 1-4

    Other: Placebo

Interventions

  • DrugAtibuclimabStudies of AtibuclimabAtibuclimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS

    Also known as: monoclonal antibody against CD14

  • OtherPlacebo

    sterile normal saline for infusion

06

What researchers measure

Primary outcomes

  1. Safety

    Treatment-emergent adverse events

    Time frame: 28 days

  2. Ventilator-free days

    The number of days alive and free of mechanical ventilation through Day 28.

    Time frame: 28 days

Secondary outcomes

  1. Change in ARDS biologic markers.

    * Change in plasma IL-8, sTNFR1, IL-6 from Day 0 to Day 4 * Change in alveolar neutrophils and total protein from Day 0 to Day 4

    Time frame: 28 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2019; primary completion for Jun 2020, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2017
First posted
Jan 11, 2017
StartEst.
Jun 2019
Primary completionEst.
Jun 2020
CompletionEst.
Jun 2020
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03017547
Lead sponsor
Implicit Bioscience
Responsible party
Sponsor
First posted
Jan 11, 2017
Start date
Jun 2019 (estimated)
Primary completion
Jun 2020 (estimated)
Completion
Jun 2020 (estimated)
Last update
May 5, 2026

Study contacts

Jan Agosti, MD
study director · Implicit Bioscience

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atibuclimab

Start the discussion